Evidence map›Paper›PMID 24402185›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014

A collagen-based scaffold delivering exogenous microrna-29B to modulate extracellular matrix remodeling.

Michael Monaghan, Shane Browne, Katja Schenke-Layland, Abhay Pandit

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Release Profile and Antibacterial Activity ofBioengineering (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Diphasic CeOBiomaterials research · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Rational Design of Immunomodulatory Hydrogels for Chronic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael Monaghan1] Network of Excellence for Functional Biomaterials, National University of Ireland, Galway, Ireland [2] Department of Cell and Tissue Engineering, Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, Germany [3] University Women's Hospital, Eberhard Karls University, Tübingen, Germany.
Shane BrowneNetwork of Excellence for Functional Biomaterials, National University of Ireland, Galway, Ireland.
Katja Schenke-Layland1] Department of Cell and Tissue Engineering, Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, Germany [2] University Women's Hospital, Eberhard Karls University, Tübingen, Germany [3] Department of Medicine/Cardiology, Cardiovascular Research Laboratories, University of California, Los Angeles, CA, USA.
Abhay PanditNetwork of Excellence for Functional Biomaterials, National University of Ireland, Galway, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Directing appropriate extracellular matrix remodeling is a key aim of regenerative medicine strategies. Thus, antifibrotic interfering RNA (RNAi) therapy with exogenous microRNA (miR)-29B was proposed as a method to modulate extracellular matrix remodeling following cutaneous injury. It was hypothesized that delivery of miR-29B from a collagen scaffold will efficiently modulate the extracellular matrix remodeling response and reduce maladaptive remodeling such as aggressive deposition of collagen type I after injury. The release of RNA from the scaffold was assessed and its ability to silence collagen type I and collagen type III expression was evaluated in vitro. When primary fibroblasts were cultured with scaffolds doped with miR-29B, reduced levels of collagen type I and collagen type III mRNA expression were observed for up to 2 weeks of culture. When the scaffolds were applied to full thickness wounds in vivo, reduced wound contraction, improved collagen type III/I ratios and a significantly higher matrix metalloproteinase (MMP)-8: tissue inhibitor of metalloproteinase (TIMP)-1 ratio were detected when the scaffolds were functionalized with miR-29B. Furthermore, these effects were significantly influenced by the dose of miR-29B in the collagen scaffold (0.5 versus 5 μg). This study shows a potential of combining exogenous miRs with collagen scaffolds to improve extracellular matrix remodeling following injury.

Indexed as

Regenerative MedicineTissue ScaffoldsAnimalsCollagen Type ICollagen Type IIIExtracellular MatrixFibroblastsHumansMatrix Metalloproteinase 8MicroRNAsPrimary Cell CultureRatsRNA, MessengerCollagen Type ICollagen Type IIIMatrix Metalloproteinase 8MicroRNAsMIRN29a microRNA, humanRNA, Messenger

Identifiers

PMID24402185
PMCPMC3983959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.